Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Kiniksa Pharmaceuticals Q1 2024 GAAP EPS $(0.25) Misses $(0.14) Estimate, Sales $79.858M Beat $78.460M Estimate

Author: Benzinga Newsdesk | April 23, 2024 07:32am
Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.14) by 78.57 percent. This is a 38.89 percent decrease over losses of $(0.18) per share from the same period last year. The company reported quarterly sales of $79.858 million which beat the analyst consensus estimate of $78.460 million by 1.78 percent. This is a 65.18 percent increase over sales of $48.345 million the same period last year.

Posted In: KNSA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist